Innovation Pharmaceuticals Inc (IPIX)

[thefamilyman]

The ScienceNews.org article you cite said,

If a drug stops the coronavirus from growing in cells in the lab, researchers should test for phospholipidosis. If the drug causes phospholipidosis, it should be discarded as a COVID-19 therapy.

I have enough confidence in the Safety Committee overseeing the current trial, and the many other scientists working with Brilacidin, that I am not concerned. Brilacidin has been through several Phase 2 trials now and phospholipidosis has not been a concern before. The ABSSSI trial was administered via IV and was a resounding success. It certainly did NOT fail due to phospholipidosis. The current Phase 2 for Covid was also administered via IV and it was not stopped due to such concerns. In other words, Brilacidin is NOT a compound that would fail in a clinical setting due to it causing phospholipidosis because it has already been through multiple clinical trials and has NOT failed.